These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2971 related articles for article (PubMed ID: 17296351)

  • 21. Epigenetic modifications in prostate cancer.
    Ngollo M; Dagdemir A; Karsli-Ceppioglu S; Judes G; Pajon A; Penault-Llorca F; Boiteux JP; Bignon YJ; Guy L; Bernard-Gallon DJ
    Epigenomics; 2014; 6(4):415-26. PubMed ID: 25333850
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The emerging roles of DNA methylation in the clinical management of prostate cancer.
    Perry AS; Foley R; Woodson K; Lawler M
    Endocr Relat Cancer; 2006 Jun; 13(2):357-77. PubMed ID: 16728568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Androgen receptor gene alterations and chromosomal gains and losses in prostate carcinomas appearing during finasteride treatment for benign prostatic hyperplasia.
    Koivisto PA; Schleutker J; Helin H; Ehren-van Eekelen C; Kallioniemi OP; Trapman J
    Clin Cancer Res; 1999 Nov; 5(11):3578-82. PubMed ID: 10589774
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histone modifications as a platform for cancer therapy.
    Espino PS; Drobic B; Dunn KL; Davie JR
    J Cell Biochem; 2005 Apr; 94(6):1088-102. PubMed ID: 15723344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epigenetic mechanisms in AML - a target for therapy.
    Oki Y; Issa JP
    Cancer Treat Res; 2010; 145():19-40. PubMed ID: 20306243
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The emerging role of epigenetics in urological cancers.
    Ramachandran K; Soloway MS; Singal R; Manoharan M
    Can J Urol; 2007 Jun; 14(3):3535-41. PubMed ID: 17594743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Epigenetic processes in malignant transformation: the role of DNA methylation in cancer development].
    Suijkerbuijk KP; van der Wall E; van Laar T; Vooijs M; van Diest PJ
    Ned Tijdschr Geneeskd; 2007 Apr; 151(16):907-13. PubMed ID: 17500342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epigenetics, disease, and therapeutic interventions.
    Lu Q; Qiu X; Hu N; Wen H; Su Y; Richardson BC
    Ageing Res Rev; 2006 Nov; 5(4):449-67. PubMed ID: 16965942
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epigenetic regulation of Myc on retinoic acid receptor beta and PDLIM4 in RWPE1 cells.
    He M; Vanaja DK; Karnes RJ; Young CY
    Prostate; 2009 Nov; 69(15):1643-50. PubMed ID: 19623543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications.
    Guan M; Zhou X; Soulitzis N; Spandidos DA; Popescu NC
    Clin Cancer Res; 2006 Mar; 12(5):1412-9. PubMed ID: 16533763
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting aberrant chromatin structure in colorectal carcinomas.
    Konishi K; Issa JP
    Cancer J; 2007; 13(1):49-55. PubMed ID: 17464246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of epigenetic alterations in pancreatic cancer.
    Sato N; Goggins M
    J Hepatobiliary Pancreat Surg; 2006; 13(4):286-95. PubMed ID: 16858539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA methylation disturbances as novel therapeutic target in lung cancer: preclinical and clinical results.
    Digel W; Lübbert M
    Crit Rev Oncol Hematol; 2005 Jul; 55(1):1-11. PubMed ID: 15886007
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting DNA methylation in cancer.
    Szyf M
    Bull Cancer; 2006 Sep; 93(9):961-72. PubMed ID: 16980240
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epigenetic changes in cancer and preneoplasia.
    Herman JG
    Cold Spring Harb Symp Quant Biol; 2005; 70():329-33. PubMed ID: 16869769
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epigenetics and cancer treatment.
    Kristensen LS; Nielsen HM; Hansen LL
    Eur J Pharmacol; 2009 Dec; 625(1-3):131-42. PubMed ID: 19836388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypermethylation of the CpG islands in the promoter region flanking GSTP1 gene is a potential plasma DNA biomarker for detecting prostate carcinoma.
    Chuang CK; Chu DC; Tzou RD; Liou SI; Chia JH; Sun CF
    Cancer Detect Prev; 2007; 31(1):59-63. PubMed ID: 17291695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
    Antunes AA; Leite KR; Sousa-Canavez JM; Camara-Lopes LH; Srougi M
    J Urol; 2009 Feb; 181(2):594-600. PubMed ID: 19084862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reversal of gene silencing as a therapeutic target for cancer--roles for DNA methylation and its interdigitation with chromatin.
    Baylin SB
    Novartis Found Symp; 2004; 259():226-33; discussion 234-7, 285-8. PubMed ID: 15171257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The next innovation cycle in toxicogenomics: environmental epigenetics.
    Reamon-Buettner SM; Mutschler V; Borlak J
    Mutat Res; 2008; 659(1-2):158-65. PubMed ID: 18342568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 149.